Skip to main content

Table 1 Patient’s characteristics and the level of clinical indicators

From: Serum BPI as a novel biomarker in asthma

 

Uncontrolled asthma (n = 39)

Controlled asthma (n = 18)

Controlled (n = 35)

Age

50.51 ± 12.13

42.17 ± 16.06

48.13 ± 8.08

Male sex (%)

35.90

44.44

34.29

BMI (kg/m2)

22.09 ± 3.07

22.56 ± 5.03

22.55 ± 3.00

Smoker (%)

38.46

33.33

25.71

Allergic history (%)

24.32

22.22

14.28

Blood

 Eosinophils counts

0.33 ± 0.41 * 109/L*

0.28 ± 0.19 * 109/L

0.15 ± 0.61 * 109/L

 Neutrophils counts

5.71 ± 2.86 * 109/L*#

3.65 ± 1.08 * 109/L

3.59 ± 1.09 * 109/L

 Total IgE (IU/mL)

367.90 ± 461.46

235.76 ± 197.31

–

 FeNO (ppb)

46.67 ± 55.80

30.10 ± 21.41

–

 Serum BPI (ng/mL)

18.10 ± 13.48*,#

12.83 ± 6.04*

6.00 ± 2.27

 hs-CRP

8.59 ± 14.88

8.82 ± 15.64

–

 FEV1% pred

63.84 ± 27.05#

72.78 ± 25.79

–

  1. Data are presented as mean ± SD. Data in the controlled and uncontrolled asthma groups were collected before inhaled corticosteroid (ICS) therapy. *p < 0.05 Comparisons were made among the three groups
  2. IgE immunoglobulin E, BPI bactericidal/permeability increasing protein, FEV1% predicted forced expiratory volume in one second as percentage of predicted volume
  3. * p < 0.05 versus healthy control group
  4. #p < 0.05 versus controlled asthma group
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us